Bone Marrow Transplantation

Top Story

FDA approves Prevymis to prevent cytomegalovirus following bone marrow transplant

November 8, 2017

The FDA today approved letermovir tablets and injection, the first treatment indicated for cytomegalovirus prophylaxis in adults who have been exposed to cytomegalovirus and underwent an allogeneic hematopoietic stem cell transplant.

More than 27,000 allogenic HSCTs are performed each year worldwide, including 8,500 in the United States. An estimated 65% to 80% of these recipients have been previously exposed to cytomegalovirus (CMV) and are at high risk for infection.

In the Journals Plus

ASCO: Even light alcohol use increases risk for cancer

November 7, 2017
Alcohol use — whether light, moderate or heavy — increases cancer risk, and public health measures are needed to reduce high-risk alcohol consumption…
Meeting News to provide live coverage of Chemotherapy Foundation Symposium

November 7, 2017
HemOnc Today and will provide live coverage of the Chemotherapy Foundation Symposium, which will be held Nov. 8-10 in New York. The 35th annual…
In the Journals Plus

Commission issues roadmap to deliver cancer moonshot initiatives

November 1, 2017
Nearly 2 years after former Vice President Joe Biden unveiled the cancer moonshot initiative, The Lancet Oncology Commission has detailed a roadmap to deliver on the…
More Headlines »

Expert Perspectives: The Latest Evidence Regarding Immune Checkpoint Inhibitors for Advanced Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

In 2016, the first immune checkpoint inhibitor was approved by the US Food and Drug Administration (FDA) for the…
More »
Meeting News

VIDEO: Emerging issues in solid organ transplantation

June 4, 2017
More »
Resource Centers


Expert Update: What's New in Essential Thrombocythemia

This activity is supported by an educational grant from Incyte Corporation.

Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms…
More »